Encapsulated mesenchymal stem cells for in vivo immunomodulation

Leukemia

Volumn 27, Issue 2, 2013, Pages 500-503

  Zanotti, L ^a   Sarukhan, A ^a,b   Dander, E ^c   Castor, M ^d   Cibella, J ^a   Soldani, C ^a   Trovato, A E ^a   Ploia, C ^a   Luca, G ^e   Calvitti, M ^e   Mancuso, F ^e   Arato, I ^e   Golemac, M ^f   Jonjic, N ^f   Biondi, A ^c   Calafiore, R ^e   Locati, M ^a,g   D'Amico, G ^c   Viola, A ^a,g  

^a HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

^b INSERM   (France)

^c UNIVERSITY OF MILANO BICOCCA   (Italy)

^d FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

^e UNIVERSITY OF PERUGIA   (Italy)

^f UNIVERSITY OF RIJEKA   (Croatia)

^g UNIVERSITY OF MILAN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

COLLAGEN TYPE 2; ETHIDIUM BROMIDE; FATTY ACID BINDING PROTEIN 4; FLUORESCEIN DIACETATE; FREUND ADJUVANT; OSTEOCALCIN; OVALBUMIN;

ACUTE GRAFT VERSUS HOST DISEASE; B LYMPHOCYTE; BIOCOMPATIBILITY; CANCER RISK; CARCINOGENESIS; CELL ENCAPSULATION; CELL FUNCTION; CELL INFILTRATION; CELL MATURATION; CELL SURVIVAL; CELL VIABILITY; CLINICAL EFFECTIVENESS; DENDRITIC CELL; ENCAPSULATED MESENCHYMAL STEM CELL; FLOW CYTOMETRY; HUMAN; IMMUNOMODULATION; IN VIVO STUDY; INFARCTION; INFLAMMATORY DISEASE; INNATE IMMUNITY; INOCULATION; LETTER; LYMPHOCYTE DIFFERENTIATION; LYMPHOID CELL; MESENCHYMAL STEM CELL; MICROENCAPSULATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; STAINING; STEM CELL TRANSPLANTATION; T LYMPHOCYTE ACTIVATION; TUMOR NECROSIS;

ADIPOCYTES; ALGINATES; ANIMALS; GLUCURONIC ACID; GRAFT VS HOST DISEASE; HEXURONIC ACIDS; IMMUNOMODULATION; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STROMAL CELLS; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, TRANSGENIC; OSTEOBLASTS; OVALBUMIN; SURVIVAL RATE; T-LYMPHOCYTES;

EID: 84873567856     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2012.202     Document Type: Letter

References (16)

1. Prockop DJ. Marrow stromal cells as stem cells for nonhematopoietic tissues. Science 1997; 276: 71-74.
2. Yagi H, Soto-Gutierrez A, Parekkadan B, Kitagawa Y, Tompkins RG, Kobayashi N et al. Mesenchymal stem cells: mechanisms of immunomodulation and homing. Cell transplantation 2010; 19: 667-679.
3. Chiesa S, Morbelli S, Morando S, Massollo M, Marini C, Bertoni A et al. Mesenchymal stem cells impair in vivo T-cell priming by dendritic cells. Proc Natl Acad Sci USA 2011; 108: 17384-17389.
4. Lee RH, Pulin AA, Seo MJ, Kota DJ, Ylostalo J, Larson BL et al. Intravenous hMSCs improve myocardial infarction in mice because cells embolized in lung are activated to secrete the anti-inflammatory protein TSG-6. Cell Stem Cell 2009; 5: 54-63.
5. Tolar J, Villeneuve P, Keating A. Mesenchymal stromal cells for graft-versus-host disease. Human gene therapy 2011; 22: 257-262.
6. Baker M. Stem-cell drug fails crucial trials. Nature News 2009; 9 September 2009.
7. Rubio D, Garcia S, De la Cueva T, Paz MF, Lloyd AC, Bernad A et al. Human mesenchymal stem cell transformation is associated with a mesenchymalepithelial transition. Exp Cell Res 2008; 314: 691-698.
8. Tolar J, Nauta AJ, Osborn MJ, Panoskaltsis Mortari A, McElmurry RT, Bell S et al. Sarcoma derived from cultured mesenchymal stem cells. Stem Cells 2007; 25: 371-379.
9. Breitbach M, Bostani T, Roell W, Xia Y, Dewald O, Nygren JM et al. Potential risks of bone marrow cell transplantation into infarcted hearts. Blood 2007; 110: 1362-1369.
10. Schrepfer S, Deuse T, Reichenspurner H, Fischbein MP, Robbins RC, Pelletier MP. Stem cell transplantation: the lung barrier. Transplant Proc 2007; 39: 573-576.
11. de Vos P, Hoogmoed CG, Busscher HJ. Chemistry and biocompatibility of alginate-PLL capsules for immunoprotection of mammalian cells. J Biomed Mater Res 2002; 60: 252-259.
12. Dufrane D, Steenberghe M, Goebbels RM, Saliez A, Guiot Y, Gianello P. The influence of implantation site on the biocompatibility and survival of alginate encapsulated pig islets in rats. Biomaterials 2006; 27: 3201-3208.
13. Doucette T, Rao G, Yang Y, Gumin J, Shinojima N, Bekele BN et al. Mesenchymal stem cells display tumor-specific tropism in an RCAS/Ntv-a glioma model. Neoplasia 2011; 13: 716-725.
14. Yanez R, Lamana ML, Garcia-Castro J, Colmenero I, Ramirez M, Bueren JA. Adipose tissue-derived mesenchymal stem cells have in vivo immunosuppressive properties applicable for the control of the graft-versus-host disease. Stem Cells 2006; 24: 2582-2591.
15. Christensen ME, Turner BE, Sinfield LJ, Kollar K, Cullup H, Waterhouse NJ et al. Mesenchymal stromal cells transiently alter the inflammatory milieu post-transplant to delay graft-versus-host disease. Haematologica 2010; 95: 2102-2110.
16. Mezey E. The therapeutic potential of bone marrow-derived stromal cells. J Cell Biochem 2011; 112: 2683-2687.